STED imaging of tau filaments in Alzheimer's disease cortical grey matter.

J Struct Biol

Discipline of Anatomy and Histology, School of Medical Sciences, The University of Sydney, Australia. Electronic address:

Published: September 2016

Alzheimer's disease (AD) involves the propagation of filaments of tau protein throughout the cerebral cortex. Imaging tau filaments and oligomers in human brain at high resolution would help contribute insight into the mechanism and progression of tauopathic diseases. STED microscopy is a nano-scale imaging technique and we aimed to test the abilities of this method for resolving tau structures within human brain. Using autopsied 50μm AD brain sections, we demonstrate that STED microscopy can resolve immunolabelled tau filaments at 77nm resolution. Ribbon-like tau filaments imaged by STED appeared smooth along their axis with limited axial undulations. STED also resolved 70-80nm wide tau puncta. Of the fluorophores tested, STAR635p was optimal for STED imaging in this tissue. This was in part due to brain tissue autofluorescence within the lower wavelength ranges (488-590nm). Further, the stability and minimal photobleaching of STAR635p allowed STED z-stacks of neurons packed with tau filaments (neurofibrillary tangles) to be collated. There was no loss of x-y image resolution of individual tau filaments through the 20μm z-stack. This demonstrates that STED can contribute to nano-scale analysis and characterisation of pathologies within banked human autopsied brain tissue. Resolving tau structures at this level of resolution provides promising avenues for understanding mechanisms of pathology propagation in the different tauopathies as well as illuminating what contributes to disease heterogeneity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsb.2016.07.003DOI Listing

Publication Analysis

Top Keywords

tau filaments
24
tau
10
sted
8
sted imaging
8
imaging tau
8
alzheimer's disease
8
human brain
8
sted microscopy
8
resolving tau
8
tau structures
8

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia.

Background: Tau PET is instrumental in tracking the longitudinal progression of Alzheimer's disease (AD). F-MK6240 is a high affinity tracer targeting the 3R/4R paired helical filaments of tau in AD. We aimed to evaluate the early phase of the natural progression of tau accumulation using F-MK6240.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.

Background: There is an urgent need for accurate and validated methods to measure plasma phosphorylated tau (p-Tau) biomarkers in Alzheimer´s disease (AD). Here we compared the performance of newly developed plasma ALZpath p-Tau217 assay to other established p-Tau assays such as Lilly p-Tau217 and Lilly p-Tau181.

Method: We included 72 participants from the Arizona Study of Aging and Neurodegenerative Disorders cohort, where we analysed antemortem collected plasma samples with ALZpath p-Tau217 as well as Lilly p-Tau217 and p-Tau181.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) continues to be the leading cause of dementia. Few treatment options exist to manage AD. It is essential to diagnose AD early to slow its progression; however, there are very limited diagnostic tools to accurately diagnose AD.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, VIC, Australia.

Background: In the presence of abnormally high amyloid (Aβ+), carriage of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism Met allele (Met66) is associated with faster clinical disease progression, greater neuronal loss and faster rate of CSF total-tau and p-tau compared to matched Val66 Aβ+ homozygotes. Aβ levels are unaffected by carriage of Met66. This suggests reduced neurotrophic support may accelerate Aβ-related neuronal dysfunction and cognitive decline.

View Article and Find Full Text PDF

Background: Tauopathy is recognized not only as a pathological substrate but also exhibits a robust correlation with the clinical manifestations of dementia, leading to diverse neuropsychiatric manifestation. However, human brain functions as networks rather than modules. The conventional query of 'Where is the lesion (regionally)?' may inadequately capture the entirety of dementia manifestations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!